와이셀라 시바리아
Weissella cibaria
📚 관련 논문 (13편)
1. BMJ Open. 2022 Dec 20;12(12):e060753. doi: 10.1136/bmjopen-2022-060753. Efficacy of probiotics in the management of halitosis: a systematic review and meta-analysis. Huang N(#)(1), Li J(#)(1), Qiao X(1), Wu Y(1), Liu Y(1), Wu C(1), Li L(2). Author information: (1)State Key Laboratory of Oral
2. Food Funct. 2024 Apr 22;15(8):4409-4420. doi: 10.1039/d4fo00195h. Effect of the probiotic Weissella cibaria CMS1 on the immune response and the oral microbiome: a randomized, double-blind, placebo-controlled, parallel study. Park MJ(1), Park SY(1), Kim KJ(2), Oh B(3), Kim JY(1)(2). Author inf
3. Int J Environ Res Public Health. 2021 Jan 28;18(3):1143. doi: 10.3390/ijerph18031143. Effects of Oral Probiotics on Subjective Halitosis, Oral Health, and Psychosocial Health of College Students: A Randomized, Double-Blind, Placebo-Controlled Study. Lee DS(1), Kim M(1), Nam SH(2), Kang MS(3)
4. BMC Oral Health. 2020 Sep 2;20(1):243. doi: 10.1186/s12903-020-01231-2. Effects of probiotic bacterium Weissella cibaria CMU on periodontal health and microbiota: a randomised, double-blind, placebo-controlled trial. Kang MS(1), Lee DS(2), Lee SA(2), Kim MS(2), Nam SH(3). Author information:
5. Microbiol Resour Announc. 2020 Aug 20;9(34):e00534-20. doi: 10.1128/MRA.00534-20. Complete Genome Sequence of Weissella cibaria Strain BM2, Isolated from Korean Kimchi. Shin JI(#)(1), Oh SG(#)(2), Bang MS(3), Jeong HW(3), Lee YJ(4), Lee SC(3), Lee GS(3), Kim S(3), Lee HH(5), Kim JH(#)(6), Oh
1. Sci Rep. 2025 May 27;15(1):18586. doi: 10.1038/s41598-025-02089-6. Anti-osteoporotic potential of a probiotic mixture containing Limosilactobacillus reuteri and Weissella cibaria in ovariectomized rats. Hossain M(1), Sultana T(1), Moon JE(2), Moon GS(3)(4), Jeong JH(5). Author information: (1)Department of Neurosurgery, College of Medicine, Soonchunhyang University, Bucheon Hospital, Bucheon 14584, South Korea. (2)Department of Biostatistics, Clinical Trial Center, Soonchunhyang University, Bucheon Hospital, Bucheon 14585, South Korea. (3)4D Convergence Technology Institute, Korea National University of Transportation, Jeungpyeong 27909, South Korea. gsmoon@ut.ac.kr. (4)Department of Biotechnology, Korea National University of Transportation, Jeungpyeong 27909, South Korea. gsmoon@ut.ac.kr. (5)Department of Neurosurgery, College of Medicine, Soonchunhyang University, Bucheon Hospital, Bucheon 14584, South Korea. neuri71@gmail.com. Postmenopausal osteoporosis poses a significant clinical challenge, as conventional therapies are often ineffective or poorly tolerated owing to adverse effects or underlying health conditions, underscoring the need for alternative treatments. This study investigated the anti-osteoporotic effects of a novel probiotic mixture combining Limosilactobacillus reuteri MGE 3301 (LR) and Weissella cibaria MGE 3110 (WC), which were selected for their anti-inflammatory properties and ability to modulate bone metabolism, in an ovariectomized rat model. Thirty-five female Wistar rats were randomly assigned to five groups: Sham, Ovariectomy (OVX), OVX with LR supplementation (OVX/LR), OVX with WC (OVX/WC), and OVX with a combination of LR and WC (OVX/LR/WC), under ARRIVE guidelines and ethical approval. Each probiotic group received 1 × 10⁹ CFU/mL/day for 16 weeks starting at 5 weeks post-OVX. Micro-computed tomography and histopathological analyses revealed that the OVX/LR/WC group had superior trabecular bone preservation compared with that in the OVX control group, with significant improvements in bone mineral density (+ 54.2%), bone volume fraction (+ 24.8%), trabecular thickness (+ 13.6%), and trabecular number (+ 20%), along with decreased trabecular separation (- 8.1%; p < 0.05). RT-qPCR analysis of bone marrow demonstrated that LR/WC suppressed osteoclastogenic mediators (RANKL: -1.35-fold; TNF-α: -2.5-fold; IL-6: -1.9-fold) while elevating osteoprotective osteoprotegerin expression (+ 3.14-fold; p < 0.05). Serum analysis showed reduced CTX-I (- 38.9%) and elevated calcium (+ 30.8%) levels in OVX/LR/WC versus OVX rats (p < 0.05), indicating suppressed bone resorption and enhanced mineral homeostasis. These findings indicate that LR/WC probiotic supplementation attenuates OVX-induced bone loss by modulating bone turnover markers and inflammatory cytokines. To our knowledge, this is the first study to assess the combined effects of LR and WC in an osteoporosis animal model, highlighting its potential as an adjunctive therapeutic candidate for osteoporosis. However, few notable imitations include undefined human dosing and the unassessed long-term safety of probiotics. Future clinical trials must validate the efficacy, elucidate mechanisms (e.g., gut-bone axis interactions), and assess safety in postmenopausal women to advance therapeutic applicability. © 2025. The Author(s). DOI: 10.1038/s41598-025-02089-6 PMCID: PMC12116856 PMID: 40425630 [Indexed for MEDLINE] Conflict of interest statement: Declarations. Competing interests: The authors declare no competing interests. Ethical approval: This study was conformed to the ARRIVE guidelines.
2. J Appl Microbiol. 2023 Nov 1;134(11):lxad237. doi: 10.1093/jambio/lxad237. Characterization of potential probiotic starter cultures of lactic acid bacteria isolated from Ethiopian fermented cereal beverages, Naaqe, and Cheka. Gizachew S(1)(2), Van Beeck W(2), Spacova I(2), Dekeukeleire M(2), Alemu A(3), Mihret W(3), Lebeer S(2), Engidawork E(1). Author information: (1)Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, P.O. Box 9086, Addis Ababa, Ethiopia. (2)Department of Bioscience Engineering, Faculty of Sciences, University of Antwerp, Groenenborgerlaan 171, 2020 Antwerp, Belgium. (3)Bacterial and Viral Diseases Research Directorate, Armauer Hansen Research Institute, P.O. Box 1005, Addis Ababa, Ethiopia. AIMS: To test the in vitro probiotic potential and starter culture capacity of lactic acid bacteria (LAB) isolated from Naaqe and Cheka, cereal-based Ethiopian traditional fermented beverages. METHODS AND RESULTS: A total of 44 strains were isolated from spontaneously fermented Ethiopian cereal-based beverages, Naaqe and Cheka with 24 putatively identified as LAB and 14 identified up to the species level. The species Limosilactobacillus fermentum (6/12; 50%) and Weissella confusa (5/12, 41.67%) were the predominant species identified from Naaqe, while the two Cheka isolates were L. fermentum and Pediococcus pentosaceus. Six LAB strains inhibited eight of the nine gastrointestinal indicator key pathogens in Ethiopia, including Escherichia coli, Salmonella enterica subsp. enterica var. Typhimurium, Staphylococcus aureus, Shigella flexneri, and Listeria monocytogenes. Three of the LAB isolates exhibited strain-specific immunostimulation in human monocytes. Based on these probiotic properties and growth, six strains were selected for in situ evaluation in a mock fermentation of Naaqe and Cheka. During primary fermentations, L. fermentum 73B, P. pentosaceus 74D, L. fermentum 44B, W. confusa 44D, L. fermentum 82C, and Weissella cibaria 83E and their combinations demonstrated higher pH-lowering properties and colony-forming unit counts compared to the control spontaneous fermentation. The same pattern was also observed in the secondary mock fermentation by the Naaqe LAB isolates. CONCLUSIONS: In this study, we selected six LAB strains with antipathogenic, immunostimulatory, and starter culture potentials that can be used as autochthonous probiotic starters for Naaqe and Cheka fermentations once their health benefit is ascertained in a clinical trial as a next step. © The Author(s) 2023. Published by Oxford University Press on behalf of Applied Microbiology International. DOI: 10.1093/jambio/lxad237 PMID: 37858306 [Indexed for MEDLINE]
3. Int J Environ Res Public Health. 2021 Apr 28;18(9):4674. doi: 10.3390/ijerph18094674. A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Acidogenic Potential of Dental Biofilms through a Tablet Containing Weissella cibaria CMU. Kang MS(1), Lee DS(2), Kim M(2), Lee SA(2), Nam SH(3). Author information: (1)Research and Development Department, Research Institute, OraPharm Inc., Seoul 04782, Korea. (2)School of Nursing, Kangwon National University, Chuncheon 24341, Korea. (3)Department of Dental Hygiene, College of Health Sciences, Kangwon National University, Samcheok 25949, Korea. The possibility of preventing dental caries by taking probiotic bacterium Weissella cibaria (W. cibaria) CMU tablets to alter the pH of the dental plaque in the oral cavity was evaluated. A randomized, double-blind, placebo-controlled trial was performed on adults aged 20 years or older with 20 or more natural teeth. Ninety-two people underwent dental scaling before being randomly assigned to the experimental group (n = 49) or the control group (n = 43). Depending on the group they belonged to, W. cibaria CMU or the placebo was administered to them once daily for 8 weeks before bedtime. Twenty-four subjects were later excluded from the study because the week 8 dosing was not smoothly performed, for a final subject count of 68. The Cariview test was used to evaluate the amount of acid produced by the dental plaque to assess the risk of caries. The results showed that although there was no significant difference between the results of the two groups, the intake of the W. cibaria CMU tablets eliminated the risk of developing dental caries from acid production in the oral flora because the W. cibaria colonizes and lives in the dental plaque and the oral cavity and suppresses acids. DOI: 10.3390/ijerph18094674 PMCID: PMC8124772 PMID: 33924761 [Indexed for MEDLINE] Conflict of interest statement: M.-S.K. is an employee of OraPharm Inc. The other authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; and in the decision to publish the results.
4. J Med Food. 2020 Jun;23(6):649-657. doi: 10.1089/jmf.2019.4603. Epub 2020 May 5. Reduction of Halitosis by a Tablet Containing Weissella cibaria CMU: A Randomized, Double-Blind, Placebo-Controlled Study. Lee DS(1), Lee SA(1), Kim M(1), Nam SH(2), Kang MS(3). Author information: (1)School of Nursing, Kangwon National University, Chuncheon, Korea. (2)Department of Dental Hygiene, School of Health Science, Kangwon National University, Samcheok, Korea. (3)R&D Department, Research Institute, OraPharm, Inc., Seoul, Korea. Halitosis is referred to as an unpleasant odor coming from the mouth. Recently, probiotics have been studied as an alternative prevention for halitosis. The aim of this study was to evaluate the effects of probiotic bacterium Weissella cibaria Chonnam Medical University (CMU)-containing tablets (1 × 108 colony forming units [CFU]/g) on oral malodor. The randomized, double-blind, placebo-controlled trial was conducted in 92 healthy adults (20-39 years of age) with bad breath. All subjects were randomly assigned to a test (probiotic, n = 49) or control (placebo, n = 43) group after dental scaling and root planing. The tablets were taken once daily for 8 weeks. Measurements included an organoleptic test (OLT), volatile sulfur compounds (VSC), bad breath improvement (BBI) scores, and the oral colonization of W. cibaria CMU. This study also assessed safety variables of adverse reactions, vital signs, and the findings of hematology and blood chemistry. Most of the variables were measured at baseline, 4, and 8 weeks. Safety-related variables were measured at baseline and 8 weeks. At week 4, a significant decrease in OLT and VSC results was observed in the test group while BBI scores were significantly reduced at week 8 (P < .05). Statistically significant intergroup differences were observed for changes in W. cibaria number at weeks 4 and 8. No safety issues were encountered in either group. These results indicate that W. cibaria CMU tablets could be a safe and useful oral care product for controlling bad breath. DOI: 10.1089/jmf.2019.4603 PMID: 32379992 [Indexed for MEDLINE]
5. Fish Shellfish Immunol. 2014 Dec;41(2):570-80. doi: 10.1016/j.fsi.2014.10.007. Epub 2014 Oct 16. In vitro and in vivo evaluation of lactic acid bacteria of aquatic origin as probiotics for turbot (Scophthalmus maximus L.) farming. Muñoz-Atienza E(1), Araújo C(2), Magadán S(3), Hernández PE(1), Herranz C(1), Santos Y(4), Cintas LM(5). Author information: (1)Grupo de Seguridad y Calidad de los Alimentos por Bacterias Lácticas, Bacteriocinas y Probióticos (Grupo SEGABALBP), Departamento de Nutrición, Bromatología y Tecnología de los Alimentos, Facultad de Veterinaria, Universidad Complutense de Madrid, 28040-Madrid, Spain. (2)Grupo de Seguridad y Calidad de los Alimentos por Bacterias Lácticas, Bacteriocinas y Probióticos (Grupo SEGABALBP), Departamento de Nutrición, Bromatología y Tecnología de los Alimentos, Facultad de Veterinaria, Universidad Complutense de Madrid, 28040-Madrid, Spain; Institute for Biotechnology and Bioengineering, Centre of Genomics and Biotechnology, University of Trás-os-Montes and Alto Douro, 5001-801 Vila Real, Portugal. (3)Centro Oceanográfico de Vigo, Instituto Español de Oceanografía (IEO), 36390 Vigo, Pontevedra, Spain. (4)Department of Microbiology and Parasitology, Faculty of Biology, University of Santiago de Compostela, 15782-Santiago de Compostela, Spain. (5)Grupo de Seguridad y Calidad de los Alimentos por Bacterias Lácticas, Bacteriocinas y Probióticos (Grupo SEGABALBP), Departamento de Nutrición, Bromatología y Tecnología de los Alimentos, Facultad de Veterinaria, Universidad Complutense de Madrid, 28040-Madrid, Spain. Electronic address: lcintas@vet.ucm.es. Turbot (Scophthalmus maximus L.) is an important commercial marine flatfish. Its production may be affected by bacterial diseases that cause severe economical losses, mainly tenacibaculosis and vibriosis, provoked by Tenacibaculum maritimum and Vibrio splendidus, respectively. An alternative or complementary strategy to chemotherapy and vaccination for the control of these diseases is the use of probiotics. In this work, we report the in vitro and in vivo potential of eight lactic acid bacteria (LAB), previously isolated from fish, seafood and fish products intended for human consumption, as turbot probiotics. Seven out of the eight LAB exerted direct antimicrobial activity against, at least, four strains of T. maritimum and V. splendidus. All LAB survived in seawater at 18 °C for 7 days, and withstood exposure to pH 3.0 and 10% (v/v) turbot bile; however, they differed in cell surface hydrophobicity (8.2-21.7%) and in their ability to adhere to turbot skin (1.2-21.7%) and intestinal (0.7-2.1%) mucus. Most of the tested strains inhibited the binding of turbot pathogens to the mucus. Leuconostoc mesenteroides subsp. cremoris SMM69 and Weissella cibaria P71 were selected based on their strong antimicrobial activity against T. maritimum and V. splendidus, good probiotic properties, and different adhesion ability to skin mucus and capacity to inhibit the adhesion of turbot pathogens to mucus. These two LAB strains were harmless when administered by bath to turbot larvae and juveniles; moreover, real-time PCR on the transcription levels of the immunity-related genes encoding IL-1β, TNF-α, lysozyme, C3, MHC-Iα and MHC-IIα in five organs (head-kidney, spleen, liver, intestine and skin) revealed the ability of these LAB to stimulate their expression in turbot juveniles, especially the non-specific immunity associated genes in mucosal tissues. Based on our results, Lc. cremoris SMM69 and W. cibaria P71 may be considered as suitable probiotic candidates for turbot farming. Copyright © 2014 Elsevier Ltd. All rights reserved. DOI: 10.1016/j.fsi.2014.10.007 PMID: 25451001 [Indexed for MEDLINE]
6. J Anim Sci. 2011 Aug;89(8):2430-9. doi: 10.2527/jas.2010-3270. Epub 2011 Mar 7. Increased dietary zinc oxide changes the bacterial core and enterobacterial composition in the ileum of piglets. Vahjen W(1), Pieper R, Zentek J. Author information: (1)Institute of Animal Nutrition, Department of Veterinary Medicine, Freie Universität Berlin, 14195 Berlin, Germany. vahjen@zedat.fu-berlin.de This study was conducted to investigate the effects of increased dietary ZnO on the bacterial core and enterobacterial composition in the small intestine of piglets that were fed diets containing a total of 124 or 3,042 mg of Zn per kilogram of diet, respectively. Zinc was supplemented to the basal diet as ZnO. Bacterial 16S rRNA genes of ileal DNA extracts were PCR-amplified with 2 bar-coded primer sets and sequenced by 454 pyrosequencing. The bacterial core species were calculated from the relative abundances of reads present in 5 of 6 samples per group and at a minimum of 5 sequences per sample. The reference database SILVA was used to assign sequence reads at an alignment minimum of 200 bases and 100% identity. Lactic acid bacteria dominated the bacterial core, but showed diverse responses to dietary ZnO. Of the dominant Lactobacillus spp., Lactobacillus reuteri was reduced due to increased dietary ZnO (44.7 vs. 17.9%; P=0.042), but L. amylovorus was not influenced. However, the changes of relative abundances of other lactic acid bacteria were more noteworthy; Weissella cibaria (10.7 vs. 23.0%; P=0.006), W. confusa (10.0 vs. 22.4%; P=0.037), Leuconostoc citreum (6.5 vs. 14.8%; P=0.009), Streptococcus equinus (0.14 vs. 1.0%; P=0.044), and S. lutetiensis (0.01 vs. 0.11%; P=0.016) increased in relative abundance. Nonlactic acid bacteria that were influenced by increased dietary ZnO included the strict anaerobic species, Sarcina ventriculi, which showed a strong numerical decrease in relative abundance (14.6 vs. 5.1%). Species of the Enterobacteriaceae increased their relative abundance, as well as species diversity, in the high dietary ZnO experimental group. Bacterial diversity indices were increased due to increased dietary ZnO (P < 0.05), which was traced back to the increase of sequences from subdominant species. Increased dietary ZnO led to an increase of less prominent species and, thus, had a major impact on the bacterial composition and diversity in piglets. This effect may help to stabilize the intestinal microbiota in the sensitive postweaning period. © 2011 American Society of Animal Science. All rights reserved. DOI: 10.2527/jas.2010-3270 PMID: 21383037 [Indexed for MEDLINE]
7. Front Microbiol. 2023 Jan 17;14:1108762. doi: 10.3389/fmicb.2023.1108762. eCollection 2023. Improvement of halitosis by probiotic bacterium Weissella cibaria CMU: A randomized controlled trial. Han HS(1), Yum H(1), Cho YD(1), Kim S(1). Author information: (1)Department of Periodontology, School of Dentistry and Dental Research Institute, Seoul National University and Seoul National University Dental Hospital, Seoul, Republic of Korea. Several in vitro and in vivo studies have evaluated the effect of probiotics on oral health; however, human clinical studies are still limited. Therefore, this study aimed to examine the effects of Weissella cibaria Chonnam Medical University (CMU)-containing tablets on halitosis. This randomized, double-blinded, placebo-controlled study included 100 adults with halitosis (age, 20-70 years). The participants were randomly assigned to the test group (n = 50) and control group (n = 50). One tablet [1 × 108 colony forming units (CFU)/tablet] was to be taken each day over 8 weeks. The concentrations of volatile sulfur compounds (VSCs), bad breath improvement scores, and oral colonization of W. cibaria were measured. Psychosocial indicators including depression, self-esteem, oral health-related quality of life, and subjective oral health status were evaluated. Most variables were assessed at baseline, 4, and 8 weeks, and W. cibaria number and safety variables were assessed at baseline and 8 weeks. Intergroup comparisons were carried out using Student's t-test, Chi-square test, or Fisher's exact test on per-protocol analysis. Intragroup differences before and after intake were analyzed using the linear mixed-effect model (LMM). Per-protocol analysis was carried out in the test group (n = 45) and control group (n = 46). Total VSC was significantly lower in the probiotics group than in the placebo group at baseline (week 0, p = 0.046) and at 8 weeks (p = 0.017). The sum of hydrogen sulfide and methyl mercaptan did not differ significantly between the groups at baseline; however, it was significantly lower in the probiotics group than in the placebo group at week 8 (p = 0.012). Bad breath improvement (BBI) scores were significantly reduced at week 8 (p = 0.006) in the probiotics group. Statistically significant intergroup differences were observed for changes in the level of W. cibaria at week 8 (p < 0.001). Psychological indicators significantly improved from baseline to week 8 in the probiotics group. No safety issues were observed in either group. The levels of W. cibaria was higher in patients with halitosis using W. cibaria CMU-containing tablets. The subjective degree of bad breath and psychological indicators were improved in patients with halitosis using W. cibaria CMU-containing tablets. Copyright © 2023 Han, Yum, Cho and Kim. DOI: 10.3389/fmicb.2023.1108762 PMCID: PMC9886871 PMID: 36733919 Conflict of interest statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
8. J Dairy Sci. 2015 Sep;98(9):5874-89. doi: 10.3168/jds.2015-9362. Epub 2015 Jul 2. Microbial cell-free extracts as sources of enzyme activities to be used for enhancement flavor development of ewe milk cheese. Calasso M(1), Mancini L(1), Di Cagno R(2), Cardinali G(3), Gobbetti M(1). Author information: (1)Department of Soil, Plant and Food Sciences, University of Bari Aldo Moro, 70126 Bari, Italy. (2)Department of Soil, Plant and Food Sciences, University of Bari Aldo Moro, 70126 Bari, Italy. Electronic address: raffaella.dicagno@uniba.it. (3)Department of Pharmaceutical Sciences, University of Perugia, 06123 Perugia, Italy. Freeze-dried cell-free extracts (CFE) from Lactobacillus casei LC01, Weissella cibaria 1XF5, Hafnia alvei Moller ATCC 51815, and Debaryomyces hansenii LCF-558 were used as sources of enzyme activities for conditioning the ripening of ewe milk cheese. Compared with control cheese (CC), CFE did not affect the gross composition and the growth of the main microbial groups of the cheeses. As shown through urea-PAGE electrophoresis of the pH 4.6-soluble nitrogen fraction and the analysis of free AA, the secondary proteolysis of the cheeses with CFE added was markedly differed from that of the CC. Compared with CC, several enzyme activities were higher in the water-soluble extracts from cheeses made with CFE. In agreement, the levels of 49 volatile compounds significantly differentiated CC from the cheeses made with CFE. The level of some alcohols, ketones, sulfur compounds, and furans were the lowest in the CC, whereas most aldehydes were the highest. Each CFE seemed to affect a specific class of chemical compounds (e.g., the CFE from H. alvei ATCC 51815 mainly influenced the synthesis of sulfur compounds). Apart from the microbial source used, the cheeses with the addition of CFE showed higher score for acceptability than the control cheese. Cheese ripening was accelerated or conditioned using CFE as sources of tailored enzyme activities. Copyright © 2015 American Dairy Science Association. Published by Elsevier Inc. All rights reserved. DOI: 10.3168/jds.2015-9362 PMID: 26142846 [Indexed for MEDLINE]
⚠️ 면책 고지
이 정보는 일반 교육 목적이며 의료 진단/처방을 대체하지 않습니다.